Go to
current issue
-
-
The UK Tobacco and Vapes Bill: a historic opportunity Lancet Respir. Med. (IF 38.7) Pub Date : 2024-12-18
No Abstract
-
On the front lines of the sepsis crisis: hurdles faced by sepsis researchers, survivors, and family advocates Lancet Respir. Med. (IF 38.7) Pub Date : 2024-12-17 Jackie Duda
No Abstract
-
Incorrect interpretation of the role of COVID-19 vaccination boosters in saving lives – Authors' reply Lancet Respir. Med. (IF 38.7) Pub Date : 2024-12-12 Margaux M I Meslé, Jeremy Brown, Marc-Alain Widdowson, Richard G Pebody
No Abstract
-
Incorrect interpretation of the role of COVID-19 vaccination boosters in saving lives Lancet Respir. Med. (IF 38.7) Pub Date : 2024-12-12 Tijl De Bie
No Abstract
-
How Glasgow's 1957 tuberculosis screening programme could help countries today Lancet Respir. Med. (IF 38.7) Pub Date : 2024-12-10 Peter Ranscombe
No Abstract
-
Caring for our interlocutors on the threshold of life and death Lancet Respir. Med. (IF 38.7) Pub Date : 2024-12-10 Magdalena Zegarra Chiappori
No Abstract
-
Evaluating tezepelumab for COPD: a missed target or unmet potential? Lancet Respir. Med. (IF 38.7) Pub Date : 2024-12-06 Mario Cazzola, Paola Rogliani, Maria Gabriella Matera
No Abstract
-
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial Lancet Respir. Med. (IF 38.7) Pub Date : 2024-12-06 Dave Singh, Christopher E Brightling, Klaus F Rabe, MeiLan K Han, Stephanie A Christenson, M Bradley Drummond, Alberto Papi, Ian D Pavord, Nestor A Molfino, Gun Almqvist, Ales Kotalik, Åsa Hellqvist, Monika Gołąbek, Navreet S Sindhwani, Sandhia S Ponnarambil
BackgroundTezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, which has shown increased expression in patients with chronic obstructive pulmonary disease (COPD) compared with healthy individuals. We aimed to assess the efficacy and safety of tezepelumab in patients with moderate to very severe COPD despite receiving triple inhaled therapy. MethodsCOURSE was a double-blind
-
GOLD COPD report: 2025 update Lancet Respir. Med. (IF 38.7) Pub Date : 2024-12-05 Priya Venkatesan
No Abstract
-
Augmenting clinical trials in asthma through digital technology, decentralised designs, and person-centric endpoints: opportunities and challenges Lancet Respir. Med. (IF 38.7) Pub Date : 2024-12-05 Job F M van Boven, Richard W Costello, Kit C B Roes, Guy G Brusselle, Kjeld Hansen, Jerry A Krishnan, Christopher E Brightling, Nicolas Roche, Salman Siddiqui, Bruce J Kirenga, Hilary Pinnock, Amy H Y Chan
Digital technologies (eg, smart inhalers, wearables, and sensors) allow for remote, objective, granular, and non-invasive data collection, making them attractive for research evaluating interventions in airways diseases with variable trajectories, such as asthma. Such technologies offer the opportunity to move towards decentralised clinical trials that are done partly or fully outside the classic clinical
-
A career development programme for women at an academic medical centre Lancet Respir. Med. (IF 38.7) Pub Date : 2024-12-05 Marika Orlov, Sarah L Rhoads, Kelsey Hills-Dunlap, Sunita Sharma, Sarah Jolley
No Abstract
-
Margareth Dalcolmo: TB expert and Brazil's “face of COVID-19” Lancet Respir. Med. (IF 38.7) Pub Date : 2024-12-02 Tony Kirby
No Abstract
-
Time to escalate quality assurance in small-cell lung cancer radiotherapy trials Lancet Respir. Med. (IF 38.7) Pub Date : 2024-12-03 Gerard M Walls, Marcel van Herk, Corinne Faivre-Finn
No Abstract
-
Time to escalate quality assurance in small-cell lung cancer radiotherapy trials – Authors' reply Lancet Respir. Med. (IF 38.7) Pub Date : 2024-12-03 Jiayi Yu, Jun Zhao, Anhui Shi
No Abstract
-
An unusual pulmonary complication of smoking Lancet Respir. Med. (IF 38.7) Pub Date : 2024-12-03 Felix Chua, Josien van Es, Rainer Doffinger, Tom Pickworth, Bart Koopman, Bekir Karakaya, Marcel Veltkamp, Maria Kokosi
Section snippets ContributorsFC conceptualised the study, provided clinical care, was involved in data collection and interpretation, and wrote the first draft of the report. JvE, TP, BKo, BKa, MV, and MK were involved in clinical care, data collection, and interpretation and contributed to the writing of the report. RD performed assays, interpreted data, and contributed to the writing of the report
-
Idiopathic inflammatory myopathies related lung disease in adults Lancet Respir. Med. (IF 38.7) Pub Date : 2024-11-29 Sameep Sehgal, Aditi Patel, Soumya Chatterjee, Anthony P Fernandez, Carol Farver, Ruchi Yadav, Yuebing Li, Sonye K Danoff, Didem Saygin, Julio A Huapaya, Erin M Wilfong, Kristin B Highland
Interstitial lung disease (ILD) is common in idiopathic inflammatory myopathies in adults, especially in patients with antisynthetase syndrome and anti-MDA5 antibody-associated dermatomyositis. Pulmonary manifestations can range from subclinical ILD to rapidly progressive respiratory failure. Coexistent myositis, characteristic skin lesions, arthritis, and Raynaud's phenomenon are common. However,
-
A new era in the treatment of acute exacerbations of asthma and COPD Lancet Respir. Med. (IF 38.7) Pub Date : 2024-11-29 Clarus Leung, Don D Sin
No Abstract
-
Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial Lancet Respir. Med. (IF 38.7) Pub Date : 2024-11-29 Sanjay Ramakrishnan, Richard E K Russell, Hafiz R Mahmood, Karolina Krassowska, James Melhorn, Christine Mwasuku, Ian D Pavord, Laura Bermejo-Sanchez, Imran Howell, Mahdi Mahdi, Stefan Peterson, Thomas Bengtsson, Mona Bafadhel
BackgroundExacerbations of asthma and chronic obstructive pulmonary disease (COPD) are important events and are associated with critical illness. Eosinophilic inflammation is a treatable trait commonly found during acute exacerbations of asthma and COPD. We hypothesised that for patients with eosinophilic exacerbations, a single injection of benralizumab, a humanised monoclonal antibody against interleukin-5
-
Top ten research priorities for breathlessness research: UK James Lind Alliance priority setting partnership Lancet Respir. Med. (IF 38.7) Pub Date : 2024-11-29 Rachael A Evans, David KH Lo, Charles C Reilly, Martin R Davies, Samantha Walker, Erika J Kennington
No Abstract
-
Associations between life-course FEV1/FVC trajectories and respiratory symptoms up to middle age: analysis of data from two prospective cohort studies Lancet Respir. Med. (IF 38.7) Pub Date : 2024-11-29 Jennifer L Perret, Dinh S Bui, Carrie Pistenmaa, Don Vicendese, Sadiya S Khan, MeiLan K Han, Raul San José Estépar, Adrian J Lowe, Caroline J Lodge, Wassim W Labaki, Jonathan V Pham, Nur Sabrina Idrose, Chamara V Senaratna, Daniel J Tan, Garun S Hamilton, Bruce R Thompson, Maitri Munsif, Alexander Arynchyn, David R Jacobs, Michael J Abramson, Shyamali C Dharmage
BackgroundLife-course lung function trajectories leading to airflow obstruction, as measured by impaired FEV1/FVC (forced vital capacity), precede the onset of chronic obstructive pulmonary disease (COPD). We aimed to investigate whether individuals on impaired FEV1/FVC trajectories have an increased burden of respiratory symptoms, including those who do not meet the spirometric criteria for COPD.
-
Respiratory symptoms and lung function trajectories: does wheeze hold the answer? Lancet Respir. Med. (IF 38.7) Pub Date : 2024-11-29 Hannah Whittaker, Jennifer K Quint
No Abstract
-
Clean air, climate targets, and respiratory health in Europe Lancet Respir. Med. (IF 38.7) Pub Date : 2024-11-29 Vijay Shankar Balakrishnan
No Abstract
-
Lifetime non-smoker survives stage IV lung cancer four times Lancet Respir. Med. (IF 38.7) Pub Date : 2024-11-25 Tony Kirby
No Abstract
-
5 years of COVID-19: equity must lead the next pandemic response in a fractured multipolar world Lancet Respir. Med. (IF 38.7) Pub Date : 2024-11-25 David S C Hui, Dorothy Yeboah-Manu, Jean B Nachega, Alfonso J Rodriguez-Morales, Tieble Traore, Markus Maeurer, Guiseppe Ippolito, Adam Zumla, Rizwan Ahmed, Osman Dar, Adeeba Kamarulzaman, Alimuddin Zumla
No Abstract
-
A composite burden score for severe asthma Lancet Respir. Med. (IF 38.7) Pub Date : 2024-11-22 Jean Bousquet, Renaud Louis, Bernardo Sousa-Pinto
No Abstract
-
Development of an asthma health-care burden score as a measure of severity and predictor of remission in SARP III and U-BIOPRED: results from two major longitudinal asthma cohorts Lancet Respir. Med. (IF 38.7) Pub Date : 2024-11-22 Joe G Zein, Nazanin Zounemat-Kerman, Ian M Adcock, Bo Hu, Amy Attaway, Mario Castro, Sven-Erik Dahlén, Loren C Denlinger, Serpil C Erzurum, John V Fahy, Benjamin Gaston, Annette T Hastie, Elliot Israel, Nizar N Jarjour, Bruce D Levy, David T Mauger, Wendy Moore, Michael C Peters, Kaharu Sumino, Elizabeth Townsend, Eugene R Bleecker
BackgroundCurrent asthma guidelines, including those of the European Respiratory Society (ERS) and American Thoracic Society (ATS), suboptimally predict asthma remission, disease severity, and health-care utilisation. We aimed to establish a novel approach to assess asthma severity based on asthma health-care burden data. MethodsWe analysed prospectively collected data from the Severe Asthma Research
-
Correction to Lancet Respir Med 2024; published online Oct 29. https://doi.org/10.1016/S2213-2600(24)00264-9 Lancet Respir. Med. (IF 38.7) Pub Date : 2024-11-22
Léna H, Greiller L, Cropet C, et al. Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08–2015 ENERGY): a randomised, open-label, phase 3 study. Lancet Respir Med 2024; published online Oct 29. https://doi.org/10.1016/S2213-2600(24)00264-9—In figure 3B
-
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial Lancet Respir. Med. (IF 38.7) Pub Date : 2024-11-21 Dongsheng Yue, Wenxiang Wang, Hongxu Liu, Qixun Chen, Chun Chen, Lunxu Liu, Peng Zhang, Guofang Zhao, Fan Yang, Guang Han, Ying Cheng, Bentong Yu, Yue Yang, Haiquan Chen, Jie Jiang, Lijie Tan, Shidong Xu, Naiquan Mao, Jian Hu, Lanjun Zhang, Xibin Zhuang
BackgroundTreatment guidelines recommend neoadjuvant or adjuvant chemotherapy, with or without immune checkpoint inhibitors, for resectable non-small-cell lung cancer (NSCLC). We report the interim results for the phase 3 RATIONALE-315 study, which aimed to investigate perioperative tislelizumab for the treatment of resectable NSCLC. MethodsRATIONALE-315 is a randomised, double-blind, placebo-controlled
-
New territories: perioperative chemoimmunotherapy in early-stage NSCLC Lancet Respir. Med. (IF 38.7) Pub Date : 2024-11-21 Yusuke Okuma
No Abstract
-
One health, one flu: the re-emergence of avian influenza Lancet Respir. Med. (IF 38.7) Pub Date : 2024-11-20 The Lancet Respiratory Medicine
No Abstract
-
Health care in Ukraine: If everybody leaves, who will stay? Lancet Respir. Med. (IF 38.7) Pub Date : 2024-11-15 Talha Burki
No Abstract
-
Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis Lancet Respir. Med. (IF 38.7) Pub Date : 2024-11-14 Amy Shackleford, Liam G Heaney, Charlene Redmond, P Jane McDowell, John Busby
BackgroundClinical remission has emerged as an important treatment goal in severe asthma; however, studies have reported variable attainment due to differences in study populations, definitions, and methods. We aimed to perform a systematic review and meta-analysis of clinical remission attainment, definitions, and correlates among patients with severe asthma who have been treated with biologics. MethodsIn
-
Asthma remission: a call for a globally standardised definition Lancet Respir. Med. (IF 38.7) Pub Date : 2024-11-14 Marek Lommatzsch, J Christian Virchow
No Abstract
-
Thoracentesis: an old story and some new sources Lancet Respir. Med. (IF 38.7) Pub Date : 2024-11-14 Emmanuel Drouin, Eric Wiel, Edouard Lansiaux, Jacalyn Duffin, Arnaud Chambellan
Section snippets Two late 18th century manuscriptsBoth of the manuscripts we feature here were written by students hearing the lectures of famous authors, but whose advice on thoracentesis is previously unknown. They are fascinating not only for expanding our understanding of these two important figures but because they provide precise descriptions of the site and technique of thoracic drainage just
-
Managing tuberculosis before the onset of symptoms Lancet Respir. Med. (IF 38.7) Pub Date : 2024-11-11 Dennis Falzon, Cecily Miller, Irwin Law, Katherine Floyd, Nimalan Arinaminpathy, Matteo Zignol, Tereza Kasaeva
No Abstract
-
First-line treatment for advanced NSCLC in older patients and those with poor performance status Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-29 Ziming Li, Shun Lu
No Abstract
-
Spirometry in female individuals Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-29 Martin R Miller, Brian L Graham, Sanja Stanojevic
No Abstract
-
Spirometry in female individuals – Authors' reply Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-29 Philippe Haouzi, Johnathan McCully
No Abstract
-
Correction to Lancet Respir Med 2024; 12: 888–900 Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-29
No Abstract
-
Correction to Lancet Respir Med 2020; 8: 696–708 Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-29
Moll M, Sakornsakolpat P, Shrine N, et al. Chronic obstructive pulmonary disease and related phenotypes: polygenic risk scores in population-based and case-control cohorts. Lancet Respir Med 2020; 8: 696–708—In this Article, a subset of participants from the SPIROMICS cohort were included in the study who were later found to have not provided consent for genetics or to have withdrawn consent for genetics
-
Health promotion in the management of respiratory diseases: an Indian perspective Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-30 Arundhati Garud, Debabani Biswas, Saibal Moitra, Subhabrata Moitra
No Abstract
-
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08–2015 ENERGY): a randomised, open-label, phase 3 study Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-29 Hervé Léna MD, Prof Laurent Greillier MD, Claire Cropet PhD, Prof Olivier Bylicki MD, Isabelle Monnet MD, Clarisse Audigier-Valette MD, Lionel Falchero MD, Prof Alain Vergnenègre MD, Pierre Demontrond MD, Margaux Geier MD, Prof Florian Guisier MD, Stéphane Hominal MD, Chrystèle Locher MD, Romain Corre MD, Prof Christos Chouaid MD, Charles Ricordel MD, GFPC 08–2015 ENERGY investigators, Hervé LENA,
Combined treatment with anti-PD-1 and anti-CTLA-4 antibodies has shown superiority over chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC), but data for older patients (aged ≥70 years) with an Eastern Cooperative Oncology Group (ECOG) performance status of 0–1 or those with an ECOG performance status of 2 are scarce. We aimed to test the superiority of the PD-1 antibody nivolumab
-
The challenge of therapeutic options for patients with lymphangioleiomyomatosis Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-25 Maria Molina-Molina
No Abstract
-
Nintedanib for patients with lymphangioleiomyomatosis: a phase 2, open-label, single-arm study Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-25 Prof Sergio Harari MD, Davide Elia MD, Antonella Caminati MD, Prof Jens Geginat PhD, Francesca Luisi MD, Prof Giuseppe Pelosi MD, Prof Claudia Specchia PhD, Olga Torre MD, Roberta Trevisan MD, Chiara Vasco PhD, Prof Maurizio Zompatori MD, Roberto Cassandro MD
Lymphangioleiomyomatosis is an ultra-rare disease mainly affecting women of childbearing age. The MILES trial showed the efficacy of sirolimus, an mTOR inhibitor, in stabilising lung function in patients with lymphangioleiomyomatosis. Drug toxicity and development of resistance are potential limitations of therapy with sirolimus. Nintedanib is a multikinase inhibitor that inhibits PDGFR, which is active
-
Youth vaping rates drop in US, but experts remain concerned Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-23 Bryant Furlow
No Abstract
-
UK COVID-19 booster vaccination programme Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-22 Priya Venkatesan
No Abstract
-
Global, regional, and national burden of pulmonary arterial hypertension, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-18
BackgroundPulmonary arterial hypertension (PAH) is a vascular disease characterised by restricted flow and high pressure through the pulmonary arteries, leading to progressive right heart failure and death. This study reports the global burden of PAH, leveraging all available data and using methodology of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) to understand the epidemiology
-
The global burden of pulmonary arterial hypertension: profound but improving? Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-18 Joseph Newman, Joanna Pepke-Zaba
No Abstract
-
Correction to Lancet Respir Med 2024; 12: 799–809 Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-18
Yu J, Jiang L, Zhao L, et al. High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial. Lancet Respir Med 2024; 12: 799-809—In this Article, figure 2A had some labelling errors with regard to the number at risk and numbered censored. These corrections
-
Mixed news on air pollution and child lung health Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-17 Udani Samarasekera
No Abstract
-
Breaking barriers: holistic assessment of ability to work in patients with sarcoidosis Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-16 Marjolein Drent, Anne-Marie Russell, Lesley Ann Saketkoo, Paolo Spagnolo, Marcel Veltkamp, Athol U Wells, representatives of the sarcoidosis community, Nicole Goh, Anne Holland, Johann Hochreiter, Selene Kock, Karolien Verheyen, Johan Verbraecken, André Cantin, Ashley Gillson, Nathan Hambly, Martin Kolb, Elisabeth Bendstrup, Anna Leistiko, Janne Møller, Riitta Kaarteenaho, Bruno Crestani, Dominique
No Abstract
-
Empirical antibiotic therapy for sepsis: save the anaerobic microbiota Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-11 Robert F J Kullberg, Bastiaan W Haak, Rishi Chanderraj, Hallie C Prescott, Robert P Dickson, W Joost Wiersinga
Antibiotics are fundamental in sepsis management; however, the optimal empirical treatment remains debated. Despite anaerobes rarely being the causative pathogen of sepsis, antibiotics targeting them are frequently used, which might lead to unintended consequences. Multiple studies have shown that depletion of commensal anaerobic gut microbes by anti-anaerobic antibiotics influences systemic immunity
-
Antimicrobial resistance: a global health emergency Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-11 The Lancet Respiratory Medicine
No Abstract
-
Survival of sepsis masked by medications that hid diverticulitis Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-10 Tony Kirby
No Abstract
-
Airway inflammation enhances the effectiveness of elexacaftor–tezacaftor–ivacaftor therapy for cystic fibrosis and CFTRN1303K mutation Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-09 Martina Gentzsch, Charles R Esther Jr, Carla M P Ribeiro
No Abstract
-
Phillip Morris sell Vectura after academic freeze-out Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-08 Talha Burki
No Abstract
-
European Respiratory Society International Congress 2024 Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-03 Priya Venkatesan
Section snippets Long-term oxygen therapy for severe hypoxaemiaTo prolong survival in patients with severe resting hypoxaemia, long-term oxygen therapy is an established treatment. The recommendation for oxygen use is for at least 15 h per day. Use for 24 h per day has been suggested to prolong survival according to a non-randomised comparison, however, the 24-h regimen can be burdensome, restrict
-
Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-01 Ruth L Goodall PhD, Prof Andrew J Nunn MSc, Prof Sarah K Meredith MBBS, Adamu Bayissa MD, Anuj K Bhatnagar MD, Prof Chen-Yuan Chiang PhD, Francesca Conradie MBBCh, Narendran Gopalan DNB, Meera Gurumurthy PhD, Bruce Kirenga PhD, Prof Nana Kiria PhD, Daniel Meressa MD, Ronelle Moodliar MMed, Nosipho Ngubane MBChB, Mohammed Rassool MBChB, Karen Sanders MSc, Rajesh Solanki MD, Prof S Bertel Squire PhD
STREAM stage 2 showed that two bedaquiline-containing regimens (a 9-month all-oral regimen and a 6-month regimen with 8 weeks of aminoglycoside) had superior efficacy to a 9-month injectable-containing regimen for rifampicin-resistant tuberculosis up to 76 weeks after randomisation. Our objective in this follow-up analysis was to assess the durability of efficacy and safety, including mortality, at
-
Towards shorter, safer, flexible, and more effective treatment regimens for drug-resistant tuberculosis Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-01 Keertan Dheda, Christoph Lange
No Abstract
更新日期：2024-11-29
Copyright © 2014-2024 北京衮雪科技有限公司 All Rights Reserved
京ICP备11026495号-2
京公网安备 11010802027423号
京公网安备 11010802027423号